RU 28965 IN THE DERMATOLOGICAL FIELD

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement4; pp. 568 - 573
• Main Authors: TAKAHASHI, OSAMU, TAKEDA, KATSUYUKI
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1988; 公益社団法人 日本化学療法学会
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement4_568

We used RU 28965, a new macrolide antibiotic, in the treatment of bacterial skin infections, and studied its efficacy. The subjects' diseases were folliculitis (5), furuncle (3), carbuncle (2), erysipelas (1), complicated phlegmon and superficial lymphangitis (1), subcutaneous abscess (1), infectious atheroma (2), acne conglobata (2) and secondary infection (3), a total of 20 cases. Administration was discontinued in two cases because of adverse effects. Clinical efficacy in the remaining 18 cases was: cure 12, marked improvement 3, and one case each of moderate improvement, slight improvement and no change. Thus the efficacy rate (moderate improvement or better) was 88.9%. Bacteria isolated from the lesions were S. aureus (6 strains), coagulase-negative Staphylococcus sp.(5) and B. subtilis (1). The overall bacterial elimination rate was 100%. Abnormal laboratory test values were 2 cases of COOMBS' test becoming positive, 2 cases of a decrease in hemoglobin and 1 case of a decrease in hematocrit. As adverse effects, digestive organ symptoms such as nausea, vomiting, etc., occurred in 2 patients. The utility rate (useful or better), calculated on the basis of overall evaluation of the above results, was 83.3%.